JP2023522212A5 - - Google Patents
Info
- Publication number
- JP2023522212A5 JP2023522212A5 JP2022563016A JP2022563016A JP2023522212A5 JP 2023522212 A5 JP2023522212 A5 JP 2023522212A5 JP 2022563016 A JP2022563016 A JP 2022563016A JP 2022563016 A JP2022563016 A JP 2022563016A JP 2023522212 A5 JP2023522212 A5 JP 2023522212A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- chain variable
- variable region
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025187491A JP2026056615A (ja) | 2020-04-17 | 2025-11-06 | 治療用ｍｕｓｋ抗体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011986P | 2020-04-17 | 2020-04-17 | |
| US63/011,986 | 2020-04-17 | ||
| US202063038633P | 2020-06-12 | 2020-06-12 | |
| US63/038,633 | 2020-06-12 | ||
| US202063112375P | 2020-11-11 | 2020-11-11 | |
| US63/112,375 | 2020-11-11 | ||
| PCT/US2021/027801 WO2021212053A2 (en) | 2020-04-17 | 2021-04-16 | Therapeutic musk antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025187491A Division JP2026056615A (ja) | 2020-04-17 | 2025-11-06 | 治療用ｍｕｓｋ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522212A JP2023522212A (ja) | 2023-05-29 |
| JP2023522212A5 true JP2023522212A5 (https=) | 2024-06-21 |
| JP7772715B2 JP7772715B2 (ja) | 2025-11-18 |
Family
ID=75850676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563016A Active JP7772715B2 (ja) | 2020-04-17 | 2021-04-16 | 治療用ｍｕｓｋ抗体 |
| JP2025187491A Pending JP2026056615A (ja) | 2020-04-17 | 2025-11-06 | 治療用ｍｕｓｋ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025187491A Pending JP2026056615A (ja) | 2020-04-17 | 2025-11-06 | 治療用ｍｕｓｋ抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11492401B2 (https=) |
| EP (1) | EP4136115A2 (https=) |
| JP (2) | JP7772715B2 (https=) |
| KR (1) | KR20230028217A (https=) |
| CN (1) | CN115843268A (https=) |
| AU (1) | AU2021256049A1 (https=) |
| BR (1) | BR112022021065A2 (https=) |
| CA (1) | CA3175597A1 (https=) |
| IL (1) | IL297295A (https=) |
| MX (1) | MX2022011856A (https=) |
| PH (1) | PH12022552483A1 (https=) |
| WO (1) | WO2021212053A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023147489A2 (en) * | 2022-01-28 | 2023-08-03 | argenx BV | Anti-musk antibodies for use in treating neuromuscular disorders |
| WO2023218099A1 (en) * | 2022-05-13 | 2023-11-16 | argenx BV | In utero treatment of a fetus having genetic disease/neuromuscular disease |
| AU2024271522A1 (en) * | 2023-05-15 | 2025-11-20 | argenx BV | Antibodies for use in agrin-deficient disorders |
| WO2025129132A1 (en) * | 2023-12-14 | 2025-06-19 | Invenra Inc. | Multispecific binding agents that target ctla4 and/or cd25 and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5814478A (en) | 1995-12-15 | 1998-09-29 | Regeneron Pharmaceuticals, Inc. | Tyrosine kinase receptors and ligands |
| US6737249B1 (en) | 1997-08-22 | 2004-05-18 | Genentech, Inc. | Agonist antibodies |
| US6624819B1 (en) | 2000-05-01 | 2003-09-23 | Broadcom Corporation | Method and system for providing a flexible and efficient processor for use in a graphics processing system |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| CA2453822C (en) | 2001-08-03 | 2011-02-22 | Tyco Healthcare Group Lp | Tissue marking apparatus and method |
| US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| JP5932670B2 (ja) * | 2010-03-11 | 2016-06-08 | ライナット ニューロサイエンス コーポレイション | ｐＨ依存性の抗原結合を有する抗体 |
| JP2011207769A (ja) | 2010-03-29 | 2011-10-20 | Arubion:Kk | 化粧料及び皮膚外用剤 |
| WO2013074636A1 (en) | 2011-11-14 | 2013-05-23 | New York University | Muscle specific receptor kinase and modulation thereof |
| US9574015B2 (en) | 2013-09-13 | 2017-02-21 | New York University | Methods for treating muscle specific receptor kinase (MuSK) myasthenia gravis with the Ig1 domain of MuSK |
-
2021
- 2021-04-16 AU AU2021256049A patent/AU2021256049A1/en active Pending
- 2021-04-16 WO PCT/US2021/027801 patent/WO2021212053A2/en not_active Ceased
- 2021-04-16 IL IL297295A patent/IL297295A/en unknown
- 2021-04-16 JP JP2022563016A patent/JP7772715B2/ja active Active
- 2021-04-16 EP EP21724109.0A patent/EP4136115A2/en active Pending
- 2021-04-16 PH PH1/2022/552483A patent/PH12022552483A1/en unknown
- 2021-04-16 CN CN202180035285.0A patent/CN115843268A/zh active Pending
- 2021-04-16 CA CA3175597A patent/CA3175597A1/en active Pending
- 2021-04-16 KR KR1020227035693A patent/KR20230028217A/ko active Pending
- 2021-04-16 BR BR112022021065A patent/BR112022021065A2/pt unknown
- 2021-04-16 MX MX2022011856A patent/MX2022011856A/es unknown
- 2021-12-30 US US17/565,994 patent/US11492401B2/en active Active
-
2022
- 2022-10-03 US US17/937,630 patent/US20230151091A1/en active Pending
-
2025
- 2025-11-06 JP JP2025187491A patent/JP2026056615A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023522212A5 (https=) | ||
| AU2022241522B2 (en) | Bispecific antibody to a-syn/igf1r and use thereof | |
| JP2022512132A5 (https=) | ||
| US20200347130A1 (en) | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof | |
| JP2020513791A5 (https=) | ||
| JP2024520188A5 (https=) | ||
| KR20160127825A (ko) | 항-mcam 항체 및 관련된 사용 방법 | |
| RS57026B1 (sr) | Anti-n3pgiu amiloid beta peptid antitela i njihova upotreba | |
| AU2018351417B2 (en) | Anti-MSLN antibody and pharmaceutical composition for cancer treatment comprising same | |
| JP2023519962A5 (https=) | ||
| JP2024515536A5 (https=) | ||
| US10836833B2 (en) | Cell engaging binding molecules | |
| JP2021511387A5 (https=) | ||
| JP2024001073A5 (https=) | ||
| JP2023506465A5 (https=) | ||
| JP2023509215A5 (https=) | ||
| JP2025505650A5 (https=) | ||
| CN113966346A (zh) | 抗a-syn/igf1r的双特异性抗体及其用途 | |
| CN114829405A (zh) | 抗bcma/抗4-1bb双特异性抗体及其用途 | |
| JP2024543822A5 (https=) | ||
| IL312060A (en) | Bispecific CD16A binders | |
| JP2024512633A5 (https=) | ||
| JP2025130076A5 (https=) | ||
| JP2023534458A5 (https=) | ||
| WO2025086564A1 (zh) | 抗人vsig4的抗体及其医药用途 |